ChromaDex Corp. has secured a partnership with Juvenis to launch cross-border sales in Tru Niagen, based in South Korea, a press release reported.
“We are pleased to execute a partnership with ChromaDex for the South Korean market,” CEO of Juvenis, Dongyeon Kim, said. “With a strong collaboration between ChromaDex and Juvenis, we look forward to building a prosperous long-term business together. Above all, we are looking forward to working with ChromaDex to help the Korean community age healthier.”
A Korean health care marketing company, Juvenis specializes in cosmetic and dietary supplement products. The brand has expanded its presence through partnerships with various trend-setting Korean companies.
“Tru Niagen is one of Amazon’s top-selling brands in the Vitamin B3 category for boosting NAD+ levels and features ChromaDex’s proprietary ingredient, Niagen (patented nicotinamide riboside or NR),” a press release states. "Between 2019 and 2050, the Republic of Korea is expected to experience the highest increase in its share of older persons, with a 23% increase in those 65 years or older."
The release goes on to explain that “nine out of the 10 countries with the largest percentage increase in the share of older persons in the world will be in Eastern and South-Eastern Asia.”
The product is now accessible at various South Korean marketplaces, including NaverSmartStore, 11thStreet, kakaoStore, Gmarket, Auction and will also be available on its local website.
“Niagen has achieved regulatory acceptance for use in supplements by the U.S. FDA. Additionally, Niagen® has been approved for use in food supplements by the European Commission, complementary medicines by the Therapeutic Goods Administration of Australia (TGA), medical foods by the Brazilian Health Regulatory Agency (ANVISA) and medical foods by the Food Standards Australia New Zealand (FSANZ). Tru Niagen has also been approved by Health Canada as a natural health product.”
To fulfill its commitment of overseeing the general NAD+ research industry, ChromaDex has also unveiled Its ChromaDex External Research Program, which has now reached over 250 material transfer agreements (MTAs) featuring Niagen, among other proprietary ingredients.
“As a pioneer of NAD+ research, we are committed to helping communities abroad discover the benefits of cellular energy, defense, repair and vitality as they age. It is our goal to provide global access to Tru Niagen® and are thrilled to partner with Juvenis to bring its proven benefits to South Korea,” said Frank Jaksch, co-founder and executive chairman of ChromaDex.